| abstract |
The present invention relates to a process for the preparation of sodium 1- [6- (morpholin-4-yl) pyrimidin-4-yl] -4- (lH-1,2,3- triazol- (I), which is characterized in that the active ingredient (5) is released from the active ingredient (5). The present invention further relates to the use of said dosage form in the preparation of said dosage form, the use of said dosage form as a medicament and the prevention of diseases, especially cardiovascular diseases, heart failure, anemia, chronic renal failure and renal failure, . |